[Federal Register: May 16, 2002 (Volume 67, Number 95)]
[Notices]               
[Page 34913]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr16my02-45]                         

-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army

 
Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Concerning Assay for the Proteolytic Activity 
of Serotype A Neurotoxin From Clostridium Botulinum

AGENCY: Department of the Army, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is 
made of the availability for licensing of U.S. Patent No. 5,965,699 
entitled ``Assay for the Proteolytic Activity of Serotype A Neurotoxin 
from Clostridium Botulinum'' issued October 12, 1999. The United States 
Government, as represented by the Secretary of the Army has rights in 
this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: A label-based assay is described , through 
modifications of substrate structure and derivatization of serum 
albumin, which can be used to determine type A proteolytic activity 
without separation of products.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-12181 Filed 5-15-02; 8:45 am]
BILLING CODE 3710-08-M